A prospective study for the correlation between soluble advanced glycation end products receptor and contrast induced nephropathy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023931

Enrollment

Unknown

Registered

2019-06-19

Start date

2019-07-01

Completion date

Unknown

Last updated

2019-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

contrast induced nephropathy

Interventions

sRAGE high-level group + low-level group:no intervention

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) volunteered to participate in this trial and signed informed consent; (2) Aged more than 18 Years; (3) Suspected as Coronary heart disease and Planned to execute Coronary angiography;

Exclusion criteria

Exclusion criteria: (1) allergy to iodine or iodine contrast agent; (2) end-stage renal disease and kidney transplantation requiring peritoneal and hemodialysis; (3) severe cardiac insufficiency and valvular heart disease, hemodynamic instability; (4) definite bacterial and fungal infections, acute and chronic inflammatory diseases, autoimmune diseases, tumors, etc.; (5) contrast agent was used within 2 weeks before admission; (6) nephrotoxic drugs were used during hospitalization.

Design outcomes

Primary

Measure	Time frame
soluble advanced glycation end products receptor;Primary Outcome Measures:The incedence of CIN;	—

Countries

China

Contacts

Public ContactChengchun Tang

Department of Cardiology, Zhongda Hospital of Southeast University Medical School

tangchengchun@hotmail.com+86 13914705570

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026